DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: TAZORAC

Summary for Tradename: TAZORAC

Patents:2
Applicants:1
NDAs:2
Suppliers: see list2
drug
patent expirations by year for
 TAZORAC

Pharmacology for Tradename: TAZORAC

Ingredient-typeRetinoids
Drug ClassRetinoid

Clinical Trials for: TAZORAC

Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne
Status: Completed Condition: Acne Vulgaris

Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis
Status: Recruiting Condition: Plaque Psoriasis

Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails
Status: Completed Condition: Brittle Nails

A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris
Status: Completed Condition: Acne Vulgaris

Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris
Status: Recruiting Condition: Acne Vulgaris

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers
Status: Completed Condition: Acne Vulgaris

Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris
Status: Completed Condition: Acne Vulgaris

A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris
Status: Completed Condition: Acne Vulgaris

Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Acne Vulgaris
Status: Completed Condition: Acne Vulgaris

Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne
Status: Completed Condition: Acne Vulgaris

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
TAZORAC
tazarotene
CREAM;TOPICAL021184Sep 29, 2000RXYes<disabled><disabled>
Allergan
TAZORAC
tazarotene
GEL;TOPICAL020600Jun 13, 1997RXYes5,914,334<disabled><disabled>
Allergan
TAZORAC
tazarotene
GEL;TOPICAL020600Jun 13, 1997RXYes6,258,830<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc